7.41
+0.21(+2.92%)
Currency In USD
| Previous Close | 7.2 |
| Open | 7.3 |
| Day High | 7.52 |
| Day Low | 7.29 |
| 52-Week High | 16.76 |
| 52-Week Low | 5.64 |
| Volume | 985,116 |
| Average Volume | 1.51M |
| Market Cap | 759.02M |
| PE | -8.33 |
| EPS | -0.89 |
| Moving Average 50 Days | 7.12 |
| Moving Average 200 Days | 8.08 |
| Change | 0.21 |
If you invested $1000 in Day One Biopharmaceuticals, Inc. (DAWN) since IPO date, it would be worth $315.32 as of October 21, 2025 at a share price of $7.41. Whereas If you bought $1000 worth of Day One Biopharmaceuticals, Inc. (DAWN) shares 3 years ago, it would be worth $379.22 as of October 21, 2025 at a share price of $7.41.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Day One to Report Second Quarter 2025 Financial Results Tuesday, August 5, 2025
GlobeNewswire Inc.
Jul 22, 2025 12:30 PM GMT
BRISBANE, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-
Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development
GlobeNewswire Inc.
Jun 10, 2025 12:30 PM GMT
Dr. Michael Vasconcelles brings more than 25 years of extensive oncology research, development and health technology expertise and corporate executive leadership to Day One Dr. Vasconcelles to drive pipeline creation and execution BRISBANE, Calif.,
Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025
GlobeNewswire Inc.
Apr 22, 2025 12:30 PM GMT
BRISBANE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life